Adaptive Biotechnologies (ADPT) reported $71.68 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 51%. EPS of -$0.09 for the same period compares to -$0.23 a year ago.
The reported revenue represents a surprise of -0.44% over the Zacks Consensus Estimate of $72 million. With the consensus EPS estimate being -$0.19, the EPS surprise was +52.63%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Adaptive Biotechnologies performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- ClonoSEQ test volume: 30,038 versus 28,950 estimated by three analysts on average.
- Revenue- Total MRD: $61.89 million versus the three-analyst average estimate of $54.78 million. The reported number represents a year-over-year change of +54.1%.
- Revenue- Total Immune Medicine: $9.79 million versus the three-analyst average estimate of $3.92 million. The reported number represents a year-over-year change of +34%.
View all Key Company Metrics for Adaptive Biotechnologies here>>>
Shares of Adaptive Biotechnologies have returned +3.4% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Adaptive Biotechnologies Corporation (ADPT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
